Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 281

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer

Open access
Guglin, Maya, Krischer, Jeffrey, Tamura, Roy, Fink, Angelina, Bello-Matricaria, Lauren, McCaskill-Stevens, Worta, Munster, Pamela N. · 2019 · Journal of the American College of Cardiology

Abstract

Background Trastuzumab is highly effective for HER2-positive breast cancer but is associated with a decline in left ventricular ejection fraction. Objective To determine whether angiotensin converting enzyme (ACE) inhibitors or beta blockers (BB) reduce the rate of trastuzumab-induced cardiotoxicity (LVEF decrease >10%, or >5% if less than 50%) and limit treatment interruptions. Methods In this double-blind, multicenter, placebo-controlled trial, cardiotoxicity and treatment interruptions in patients with HER2-positive breast cancer treated with trastuzumab for 12 months were evaluated over a 2-year period. Patients were stratified by anthracycline use and then randomized to receive lisinopril, carvedilol, or placebo. Results The study included 468 women, 51±10.7 years old. For the entire cohort, cardiotoxicity was comparable in the three arms and occurred in 32% patients on placebo, 29% on carvedilol, and 30% on lisinopril. For patients receiving anthracyclines, the event rates were higher in the placebo group (47%) than in the lisinopril (37%) and the carvedilol (31%) groups. Cardiotoxicity-free survival was longer on both carvedilol (HR 0.49, 95% confidence intervals 0.27, 0.89, p=0.009) or lisinopril (HR 0.53, CI 0.30, 0.94, p=0.015) than on placebo. In the whole cohort, as well as in the anthracycline arm, patients on active therapy with either ACE inhibitor or BB experienced fewer interruptions in trastuzumab than those on placebo. Conclusions In patients with HER2-positive breast cancer treated with trastuzumab, both lisinopril and carvedilol prevented cardiotoxicity in patients receiving anthracyclines. For such patients, lisinopril or carvedilol should be considered to minimize interruptions of trastuzumab.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2019.03.495

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 281

Metadata

Authors
Guglin, M., Krischer, J., Tamura, R., Fink, A., Bello-Matricaria, L., McCaskill-Stevens, W., & Munster, P. N.
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2019-06
Volume
73
Issue
22
Pages
2859-2868
ISSN
0735-1097 (ISSN-L)
OpenAlex
W2948656647
Cited by
281
References
29
FWCI
26.73
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer. https://app.cochat.ai/papers/10.1016/j.jacc.2019.03.495
The paper
Guglin, M., Krischer, J., Tamura, R., Fink, A., Bello-Matricaria, L., McCaskill-Stevens, W., & Munster, P. N. (2019). Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer. Journal of the American College of Cardiology. https://doi.org/10.1016/j.jacc.2019.03.495

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.